PerkinElmer (NYSE:PKI) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $1.29 billion-$1.29 billion, compared to the consensus revenue estimate of $1.19 billion.
Shares of PKI traded down $2.75 during trading hours on Tuesday, hitting $127.81. The company had a trading volume of 1,350,726 shares, compared to its average volume of 996,559. PerkinElmer has a 52-week low of $88.27 and a 52-week high of $162.70. The firm has a market cap of $14.32 billion, a P/E ratio of 34.58, a P/E/G ratio of 0.99 and a beta of 1.19. The company has a quick ratio of 0.96, a current ratio of 1.35 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $130.77 and its 200 day moving average price is $136.41.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Tuesday, February 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.01 by $0.95. PerkinElmer had a return on equity of 21.57% and a net margin of 12.74%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter in the previous year, the business earned $1.35 EPS. PerkinElmer’s revenue was up 68.2% compared to the same quarter last year. On average, research analysts expect that PerkinElmer will post 7.12 EPS for the current fiscal year.
PKI has been the topic of a number of research analyst reports. Wells Fargo & Company upgraded PerkinElmer from an equal weight rating to an overweight rating and boosted their price target for the company from $140.00 to $175.00 in a report on Thursday, January 7th. Citigroup upped their target price on PerkinElmer from $150.00 to $155.00 in a report on Wednesday, February 3rd. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $133.93.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: QQQ ETF
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.